This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kern, W V Articles by Arnold, R Search for Related Content PubMed PubMed Citation Articles by Kern, W V Articles by Arnold, R

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 March; 38(3): 465-472

A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Section of Infectious Diseases and Clinical Immunology, University Hospital and Medical Center, Ulm, Germany.

ABSTRACT

Fluoroquinolone prophylaxis in patients with profound neutropenia may be useful for preventing gram-negative bacterial infection, but it is ineffective against gram-positive bacterial infections in the bloodstream, particularly those caused by streptococci and coagulase-negative staphylococci, which appear to have emerged as significant causes of morbidity, decreased treatment efficacy, and the increased costs of empiric antimicrobial therapy. In a prospective, randomized, open trial, we evaluated the efficacy and safety of oral roxithromycin (150 mg twice daily) as additional antibacterial prophylaxis in 131 adult patients with acute leukemia and bone marrow transplant recipients receiving oral ofloxacin. In comparison with patients given ofloxacin alone, fewer patients receiving ofloxacin plus roxithromycin developed bacteremia caused by viridans group streptococci (incidence, 9 versus 0%; P = 0.03), while the incidence of bacteremia caused by other organisms, the incidence of febrile episodes from any cause, the risk of infection-associated complications (including prolonged or secondary fever, pneumonia, septic shock, need for mechanical ventilation, and/or infection-related death), and antimicrobial usage for therapy were comparable between both groups. Adverse events possibly related to the study drugs were slightly more common among the patients receiving the combination treatment (P = 0.05). Although effective for the prevention of streptococcal bacteremia, the addition of roxithromycin to a fluoroquinolone should not be used routinely as a prophylactic regimen in patients with profound neutropenia, but it might be considered and may be useful for cancer patients with a particularly high risk of streptococcal infection and related complications.

This article has been cited by other articles:

• Gafter-Gvili, A., Paul, M., Fraser, A., Leibovici, L. (2007). Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 59: 5-22 [Abstract] [Full Text]  
• Gafter-Gvili, A., Fraser, A., Paul, M., Leibovici, L. (2005). Meta-Analysis: Antibiotic Prophylaxis Reduces Mortality in Neutropenic Patients. ANN INTERN MED 142: 979-995 [Abstract] [Full Text]  
• Cruciani, M., Malena, M., Bosco, O., Nardi, S., Serpelloni, G., Mengoli, C. (2003). Reappraisal With Meta-Analysis of the Addition of Gram-Positive Prophylaxis to Fluoroquinolone in Neutropenic Patients. JCO 21: 4127-4137 [Abstract] [Full Text]  
• Alcaide, F., Benítez, M. A., Carratalà, J., Gudiol, F., Liñares, J., Martín, R. (2001). In Vitro Activities of the New Ketolide HMR 3647 (Telithromycin) in Comparison with Those of Eight Other Antibiotics against Viridans Group Streptococci Isolated from Blood of Neutropenic Patients with Cancer. Antimicrob. Agents Chemother. 45: 624-626 [Abstract] [Full Text]  
• Gomez-Martin, C., Sola, C., Hornedo, J., Perea, S., Lumbreras, C., Valenti, V., Arcediano, A., Rodriguez, M., Salazar, R., Cortes-Funes, H., Hidalgo, M. (2000). Rifampin Does Not Improve the Efficacy of Quinolone Antibacterial Prophylaxis in Neutropenic Cancer Patients: Results of a Randomized Clinical Trial. JCO 18: 2126-2134 [Abstract] [Full Text]  
• Kerr, K. G. (1999). The prophylaxis of bacterial infections in neutropenic patients. J Antimicrob Chemother 44: 587-591 [Full Text]  
• Ford, C. D., Reilly, W., Wood, J., Classen, D. C., Burke, J. P. (1998). Oral Antimicrobial Prophylaxis in Bone Marrow Transplant Recipients: Randomized Trial of Ciprofloxacin versus Ciprofloxacin-Vancomycin. Antimicrob. Agents Chemother. 42: 1402-1405 [Abstract] [Full Text]